<DOC>
	<DOCNO>NCT00955149</DOCNO>
	<brief_summary>Primary sclerosing cholangitis ( PSC ) chronic inflammatory condition bile duct unknown etiology . It characterize diffuse inflammation stricturing entire biliary tree , eventually result cirrhosis liver . Patients PSC increase risk development cholangiocarcinoma ( CCA ) , cancer arise bile duct epithelium . This risk estimate approximately 1 1.5 % per year . It postulate chronic inflammatory change biliary epithelium promote CCA formation . The prognosis CCA fatal . The potentially curative therapy surgical ; however , minority patient qualify surgical treatment . Several study demonstrate overexpression epidermal growth factor receptor ( EGFR ) CCA cell . EGFR type 1 tyrosine kinase promote cell proliferation , migration alter cell adhesion - typical characteristic malignant neoplasia . In CCA cell , EGFR-activation sustain result cancer progression . In human CCA sample , EGFR-expression correlate high histologic grade , poor prognosis , risk recurrence . The EGFR gene locate short arm chromosome 7 ( 7p12 ) . Chromosomal abnormality bile duct epithelium , particularly trisomy 7 ( i.e . three copy chromosome 7 ) detect biliary epithelial sample obtain endoscopic retrograde cholangiopancreatography ( ERCP ) PSC patient . The finding cell trisomy 7 precede development aneuploidy multiple chromosomal abnormality number patient , latter chromosomal abnormality characteristic CCA . Trisomy 7 amplifies gene EGFR thereby presumably promote overexpression growth factor receptor . In cohort patient Trisomy 7 Primary Sclerosing Cholangitis patient follow 1 year , rate development Cholangiocarcinoma 35 % ( n=37 , Dr. Gores , unpublished observation ) . Patients without cytologic abnormality minimal risk development CCA . Erlotinib ( Tarceva ) human EGFR type 1 tyrosine kinase inhibitor . Tarceva receive FDA approval single agent treatment patient locally advanced metastatic non-small cell lung cancer . In randomized , double blind , placebo control trial 731 patient , receive 150 mg Tarceva placebo daily , median survival prolong 6.7 month 4.7 month ( p &lt; 0.001 ) . Analysis epidermal growth factor receptor expression ( 45 % total study patient ) demonstrate great survival benefit EGFR positive patient . Tarceva combination Gemcitabine also FDA approve first line therapy patient locally advance , unresectable metastatic pancreatic cancer . Our central hypothesis patient trisomy 7 carcinogenic change include EGFR overexpression . EGFR blockade inhibit growth/survival advantage premalignant clone eliminate biliary epithelium . As initial step towards test hypothesis , tolerability Tarceva patient population need establish . This study assist determine safety tolerability Tarceva patient primary sclerosing cholangitis . This study follow Phase 2 randomize control trial Tarceva patient Primary Sclerosing Cholangitis Trisomy 7 .</brief_summary>
	<brief_title>Erlotinib Chemoprevention Trisomy 7 Positive Primary Sclerosing Cholangitis ( PSC )</brief_title>
	<detailed_description />
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Cholangitis</mesh_term>
	<mesh_term>Trisomy</mesh_term>
	<mesh_term>Cholangitis , Sclerosing</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Male female patient &gt; 18 year age , able provide write informed consent . Diagnosis Primary Sclerosing Cholangitis . Scheduled ERCP part clinical care . Diagnosed trisomy 7 cytologic test . Willingness utilize adequate contraception ( female , evidence postmenopausal least 6 month use contraceptive pill ; female male , surgically sterile , use two form barrier contraception ) screen least one month trial . Cholangiocarcinoma , hepatocellular carcinoma , pancreatic adenocarcinoma malignancy &lt; =3 year registration . Other liver disease determine standard clinical , serological , image histological criterion . Secondary cause sclerosing cholangitis ( IgG cholangiopathy , autoimmune , postsurgical biliary stricture , radiation , human immunodeficiency syndrome ) . Cholestasis bilirubin &gt; 1.6 mg/dl ( normal range : 0.1 1.0 mg/dL ) . Decompensated cirrhosis , ChildPugh Class B C. Child A cirrhosis portal hypertension ( i.e. , splenomegaly , esophageal gastric varix , platelet count &lt; 100,000/µl [ normal range : 150 450 x 103/µL ] ) . Transaminase ( AST [ norm . : 848 U/L ] , ALT [ norm . : 755 U/L ] ) elevation three time upper limit normal range . Pregnancy . Nursing mother . Uncontrolled intercurrent illness . Concurrent administration CYP3A modulators , Antiepileptics , Rifampin , St. Johns wort , Ketoconazole , protonpumpinhibitors . Men woman unwilling employ adequate contraception . Abnormalities cornea history . Moderate diarrhea define defecation frequency equal 4/d colon , equal 8/d patient pouch , high ostomy output ostomy . Known interstitial lung disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Primary sclerosing cholangitis</keyword>
	<keyword>Trisomy 7</keyword>
	<keyword>Cholangiocarcinoma</keyword>
	<keyword>Chemoprevention</keyword>
	<keyword>Erlotinib</keyword>
</DOC>